E. A. McKie

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

R Rampling, G. Cruickshank, Vakis Papanastassiou et al. · Gene Therapy · 2000 · 594 citations

Neuro-oncology, Null Mutant 1716, Medicine +11

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - evaluation of a potentially effective clinical therapy

E. A. McKie, AR MacLean, AD Lewis et al. · British Journal of Cancer · 1996 · 115 citations

Viral Replication, Molecular Virology, Primary Human Cns +10

The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34

Stuart M. Brown, Alasdair Maclean, E. A. McKie et al. · Journal of Virology · 1997 · 97 citations · Full text

Virulence Factor Icp34.5, Molecular Virology, Cell Nuclear Antigen +13

Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17

Aidan Dolan, E. A. McKie, Alasdair Maclean et al. · Journal of General Virology · 1992 · 46 citations

Viral Replication, Genetics, Viral Pathogenesis +18

Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector – potential glioblastoma targeting

E. A. McKie, D. I. Graham, SM Brown · Gene Therapy · 1998 · 41 citations

Neuro-oncology, Glioma, Gfap Promoter +8